Abstract:Background: Non-alcoholic fatty liver disease is the fastest growing cause of liver disease in the Western world, yet there is no approved pharmacotherapy. While lifestyle modifications remain the mainstay of treatment, only a proportion of individuals are able to make or sustain them, and so more treatment options are required. Aim: To review the potential benefit of drugs used in clinical practice, those entering phase II trials, and compounds being investigated in pre-clinical studies. Methods: A literature search was performed using PubMed to identify relevant studies; linked references were also reviewed. Results: Vitamin E and pioglitazone have shown efficacy in non-alcoholic steatohepatitis (NASH), but long-term safety concerns, specifically bladder cancer and osteoporosis with pioglitazone, have limited their use. GLP-1 analogues and SGLT-2 inhibitors are currently approved for use in diabetes, have shown early efficacy in NASH and also have beneficial cardiovascular effects. Peroxisome proliferator-activator receptors and FXR agonists have potent effects on lipogenesis, inflammation and fibrosis, respectively, with their efficacy and safety being currently tested in phase 3. As inflammation and apoptosis are key features of NASH agents modulating these pathways are of interest; CCR2/5 antagonists downregulate inflammatory pathways and reduce fibrosis with caspase and apoptosis signal-regulating kinase 1 inhibitors reducing apoptosis and fibrosis. Conclusions: Rising demand and an improved understanding of NASH pathophysiology has led to a surge in development of new therapies. Tailoring pharmacotherapy to the dominant pathogenic pathway in a given patient along with use of combination therapy is likely to represent the future direction in treatment of patients with NASH.

Current strategies for nonalcoholic fatty liver disease treatment (Review)

Natural Products in the Modulation of Farnesoid X Receptor Against Nonalcoholic Fatty Liver Disease

Current treatment of non‐alcoholic fatty liver disease

Diagnostic and therapeutic strategies for non-alcoholic fatty liver disease

Emerging targets and potential therapeutic agents in non-alcoholic fatty liver disease treatment

Current Therapeutical Approaches Targeting Lipid Metabolism in NAFLD

Shedding light on non-alcoholic fatty liver disease: Pathogenesis, molecular mechanisms, models, and emerging therapeutics

Molecular Mechanism Pathways of Natural Compounds for the Treatment of Non-Alcoholic Fatty Liver Disease

Advancements in the treatment of non-alcoholic fatty liver disease (NAFLD)

Treatments for NAFLD: State of Art

Current insights in molecular characterization of non-alcoholic fatty liver disease and treatment

Current Innovations in Nutraceuticals and Functional Foods for Intervention of Non-Alcoholic Fatty Liver Disease

Current and upcoming pharmacotherapy for non-alcoholic fatty liver disease

Pharmacological advances in the treatment of nonalcoholic fatty liver diseases : focused on global results of randomized controlled trials

Non-Alcoholic Fatty Liver Disease (NAFLD) and its Recent Therapeutic Strategies

Pharmacological Treatment for Non-alcoholic Fatty Liver Disease

Current, emerging, and potential therapies for non-alcoholic steatohepatitis

Review article: new treatments in non-alcoholic fatty liver disease

Current pharmacologic treatment of nonalcoholic fatty liver disease

Natural Active Compounds from Plant Food and Chinese Herbal Medicine for Nonalcoholic Fatty Liver Disease

Emerging novel targets for nonalcoholic fatty liver disease treatment: Evidence from recent basic studies